StockNews.AI
COGT
StockNews.AI
190 days

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

1. Cogent Biosciences will present bezuclastinib data at AAAAI 2025. 2. Focus on long-term benefits for systemic mastocytosis patients. 3. Bezuclastinib targets KIT D816V mutation linked to several cancers. 4. The company also studies FGFR2 inhibitors and other targeted therapies.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical data could enhance investor confidence, similar to past successes.

How important is it?

Upcoming data may significantly influence investor outlook and company's market position.

Why Long Term?

The ongoing trials and upcoming presentations may yield sustained interest over time.

Related Companies

GIST
February 10, 2025 09:15 ET  | Source: Cogent Biosciences, Inc. WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced an upcoming poster for bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in San Diego, CA, February 28-March 3, 2025. The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use. Poster Details Poster Presentation Title: Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of BezuclastinibSession Date and Time: March 1, 2025 – 9:45am – 10:45am PT (12:45pm – 1:45pm ET)Session Title: Novel Mechanisms of Mast Cells, Basophils and IgEPoster Number: 520Location: San Diego Convention Center, Ground Level, Hall A About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X. Contact:Christi WaarichSenior Director, Investor Relationschristi.waarich@cogentbio.com617-830-1653

Related News